
Sign up to save your podcasts
Or
Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue control and drug development.
Read the full article:
https://www.thelancet.com/journals/laninf/article/ S1473-3099(24)00030-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laninf
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Prasad Kulkarni discusses a new Phase I trial in The Lancet Infectious Diseases on a dengue monoclonal antibody also known as VIS513 in healthy adults. In addition, he highlights the wider implications of this for dengue control and drug development.
Read the full article:
https://www.thelancet.com/journals/laninf/article/ S1473-3099(24)00030-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laninf
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
138 Listeners
1,809 Listeners
2,057 Listeners
323 Listeners
500 Listeners
3,341 Listeners
112,557 Listeners
1,137 Listeners
268 Listeners
192 Listeners
368 Listeners
159 Listeners
22 Listeners
0 Listeners
0 Listeners
2 Listeners
2 Listeners
0 Listeners
1 Listeners
0 Listeners
0 Listeners
0 Listeners
1 Listeners
1 Listeners
0 Listeners
0 Listeners
0 Listeners
31 Listeners
0 Listeners
85 Listeners
0 Listeners
3 Listeners
0 Listeners
0 Listeners